Poly(ADP-Ribose) Polymerase Mediates Inflammation in a Mouse Model of Contact Hypersensitivity
Journal of Investigative Dermatology (2009) 129, 234-238; doi:10.1038 /jid.2008 published online 17 July 2008 TO THE EDITOR Contact hypersensitivity (CHS) is a form of a delayed type of hypersensitivity, a classic T-cell-mediated, clinically important phenomenon elicited by small molecular weight molecules (haptens) that bind to host proteins to form a complete allergen (Grabbe and Schwarz, 1998) . The CHS reaction can be divided in to two phases: sensitization and elicitation. The elicitation phase is dominated by the production of proinflammatory cytokines and cellular infiltration by lymphocytes and granulocytes. Infiltration is accompanied by strong oxidative stress due to the formation of superoxide, nitric oxide, peroxynitrite, and further reactive species (Rowe et al., 1997; Ross et al., 1998) .
The poly(ADP-ribose) polymerase (PARP) superfamily consists of 17 members (Ame et al., 2004) . A subgroup of these enzymes can be activated by DNA single-strand breaks and aberrant DNA forms (Ame et al., 1999; Schreiber et al., 2006) . In tissues and cells, PARP-1 is responsible for most of the PARP activity due to its abundance and high catalytic activity. Activated PARP-1 uses NAD þ as a substrate and synthesizes the formation of poly(ADPribose) polymers covalently attached to different acceptor proteins. The presence of poly(ADP-ribose) polymers may regulate the functions of the acceptor proteins (Schreiber et al., 2006) . Inhibition of PARP activity or knocking out the PARP-1 gene has been shown to suppress inflammatory reactions such as colitis, arthritis, and uveitis (Shall and De Murcia, 2000; Cuzzocrea, 2005) . Prevention of cellular dysfunction and inhibition of NF-kB activation have been proposed to be the mechanisms underlying the anti-inflammatory effects of PARP inhibition/knockout .
Poly(ADP-ribose) polymerase plays a role in the regulation of the transcription of various inflammatory mediators such as cytokines, chemokines, inducible nitric oxide synthase, and matrix metalloproteinases (MMPs).
In our previous report, we have demonstrated peroxynitrite production, DNA breakage, and poly(ADP-ribose) formation during the elicitation phase of the CHS . Moreover, we have shown that peroxynitrite, superoxide, and hydrogen peroxide impair proliferation and viability of HaCaT keratinocytes . PARP inhibitors prevented necrotic cell death with a slight increase in apoptotic DNA fragmentation and also reduced cytokine-induced expression of IL-8 and ICAM-1 in HaCaT cells. . Kehe et al. (2008) reported similar findings in a model of sulfur mustard-induced cell death of HaCaT cells. They also found that the PARP inhibitor 3-aminobenzamide diverted the vesicant-induced necrotic cell death toward apoptosis.
The aim of this study was to investigate (1) whether PARP activation contributes to CHS and (2) whether the role of PARP in CHS is related to regulation of chemokine expression and MMP activation.
In our current experiment, we have investigated the effect of the PARP inhibitor PJ34 in the mouse model of oxazolone-induced CHS as described earlier . Similar to the majority of PARP inhibitors, PJ34 (see structural formula on Figure 1 ) inhibits the enzyme as an NAD þ analog (Jagtap et al., 2002; Jagtap and Szabo, 2005) . PJ34 has been shown to exert potent cytoprotective and antiinflammatory effects in various cell-based and animal studies Jagtap and Szabo, 2005) .
Animal experiments conform with the ''Guide for the Care and Use of Laboratory Animals'' published by the US National Institute of Health, and the treatment protocol was approved by the institutional Ethical Committee. Thirty female CD1 mice were randomized into three groups (control, CHS, CHS þ PJ34) and were sensitized by smearing 100 ml of 2% (w/v) oxazolone onto the preshaved abdominal wall. Oxazolone was dissolved in acetone:olive oil 1:4 mixture. (The control group was mock-sensitized with the vehicle.) One week after sensitization, mice were treated with i.p. injection of phosphate-buffered saline (control group and CHS group) or with PJ34 (10 mg kg À1 ) before the application of 4 Â 10 ml 0.5% (w/v) oxazolone onto the inner and outer surface of the ear on both sides. After 24 hours, thickness of ears was measured and tissue samples are taken for laboratory investigations. Oxazolone challenge of presensitized animals resulted in the swelling of the ears (Figure 2a (a) CHS reaction was induced in oxazolonesensitized mice by smearing oxazolone on both sides of the ears (n ¼ 10). Sections of ears were stained with hematoxylin and eosin, and enzyme histochemistry was used to detect peroxidase activity. Oxazolone-induced CHS resulted in edema in the dermis, which could be suppressed by PJ34 treatment. PJ34 treatment reduced the number of peroxidase-positive cells in the ears (n ¼ 10). (Bar ¼ 1,000 mm for the images of hematoxylin-and-eosin staining and 400 mm for the images of peroxidase staining).
(b) Measurement of ear thickness provided further support for the involvement of PARP in CHS-induced inflammation. Ears of mice in the CHS group (n ¼ 10) were markedly thicker due to edema formation. PJ34 significantly reduced edema (n ¼ 10; ***Po0.001, # Po0.05). (c) In line with the peroxidase staining, myeloperoxidase activity of ear lysates also indicated granulocyte infiltration in the CHS group (n ¼ 10). MPO activity was efficiently reduced by PJ34 pretreatment. (n ¼ 10, ***Po0.001, # Po0.05).
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activity of ear lysates (Figure 2a and c).
Epicutaneously applied haptens may also induce nonantigen-specific irritant dermatitis (Grabbe et al., 1996) . To see whether PARP inhibition also suppresses irritant dermatitis, we have determined the effect of PJ34 on 12-O-tetradecanoyl-phorbol 13-acetate-induced ear swelling. 12-O-tetradecanoyl-phorbol 13-acetate (10 ml, 0.05% w/v) was smeared onto both sides of the ears of female mice (n ¼ 8 animals per group) immediately followed by PJ34 or vehicle treatment as described above. 12-O-tetradecanoyl-phorbol 13-acetate induced a less severe inflammation as compared with oxazolone, and the PARP inhibitor significantly reduced ear swelling and inhibited cellular infiltration (MPO activity) ( Figure S1 ), indicating that it targets general inflammatory pathways rather than specific immune response. Poly(ADP-ribose) polymerase-1 has been shown earlier to regulate the expression of chemokines in various models of inflammation . Macrophage inflammatory protein-1a, one of the main chemoattractant of neutrophil granulocytes, and other proinflammatory chemokines/cytokines such as macrophage inflammatory protein-2, tumor necrosis factor-a, and IL-1b were induced in the allergic reaction and was reduced by PJ34 (Figure 3a) . Levels of these cytokines were determined with commercially available (R&D System, Minneapolis, MN) ELISA assay kits.
We also set out to investigate whether PARP activity regulates MMP expression in CHS. MMPs are secreted by a variety of skin-resident and infiltrating cells, including fibroblasts, endothelial cells, macrophages, neutrophils, and lymphocytes. These enzymes are expressed as zymogens, which are subsequently processed either by other proteolytic enzymes or by free radicals triggering structural changes resulting in full-length active MMPs (Pacher et al., 2003; Le et al., 2007) . The MMP activity is counterbalanced by a family of tissue inhibitors, called tissue inhibitors of metalloproteinases (TIMPs). Metalloproteinase activity of ear extracts was determined by gelatin zymography as described by Pacher et al. (2002) . In CHS samples, a band with an apparent molecular weight of 89-92 kDa was found to be upregulated. PJ34 treatment suppressed this activity (Figure 3b ). The molecular weight (89-92 kDa) suggested that MMP-9 expression can be responsible for the appearance of this band. By western blotting, we have detected an increase in the level of MMP-9 upon inflammation and PJ34 reversed MMP expression (Figure 3b) . Moreover, we have detected a decreased expression of TIMP-2 in CHS samples, which was prevented by PJ34 pretreatment (Figure 3b) . Hereby, we provide evidence for the involvement of PARP in the pathomechanism of inflammation in CHS. PARP inhibition reduced edema (ear swelling) and the migration of inflammatory cells to the site of inflammation. Reactive oxygen and nitrogen intermediates (ROI and RNI, respectively) are produced in large quantity in inflammatory conditions including CHS and constitute important pathogenetic factors triggering endothelial dysfunction . ROI and RNI can stimulate the DNA breakage-PARP-1 activation pathway that has been shown to mediate endothelial dysfunction in other experimental settings such as in diabetic blood vessels (Soriano et al., 2001; Pacher and Szabo, 2005) . We hypothesize that similar mechanisms may underlie the anti-inflammatory and chemokines (macrophage inflammatory protein-1a, macrophage inflammatory protein-2) were determined from ear lysates by using commercially available (R&D System) ELISA kits. All cytokines and chemokines investigated were upregulated in the CHS samples (n ¼ 10) as compared with control (n ¼ 10). PJ34 inhibited the expression of all four cytokines/chemokines. (n ¼ 10; *Po0.05, ***Po0.001, # Po0.05). (b) Expression and activation of MMPs have been studied by zymography and western blot, respectively. A 89-92 kDa proteinase activity is detected in the inflamed ears, whereas its activity was abrogated upon pretreatment with PJ34. Western blotting with an MMP-9 antibody verified that there is a mild increase in the expression of MMP-9, suggesting MMP-9 to be implicated in the inflammatory process. TIMP-2 protein level decreased in CHS samples, and this decreased TIMP-2 expression was prevented by PJ34 treatment (n ¼ 6 in each group). Minor adjustment to contrast has been made on the western blot images.
effects of PARP inhibition in CHS (see Figure S2 ). Various skin-resident cell types and immigrating inflammatory cells can produce ROI and RNI (Trouba et al., 2002; Okayama, 2005) . Oxidative stress may cause DNA breakage and activate PARP-1 in endothelial cells, which may cause endothelial dysfunction through depletion of NAD þ and ATP. PARP inhibitors may interfere with this pathway at two points. They may directly prevent the depletion of energy metabolites and may reduce the amount of ROI/RNI produced during inflammation. As most ROI/RNI are likely produced by the infiltrating granulocytes, inhibition of granulocyte migration from the circulation to the site of inflammation may result in suppressed ROI/RNI production. Indeed, our results indicate that PARP inhibition markedly inhibits the extravasation of granulocytes as indicated by peroxidase staining and MPO activity measurements of ear lysates. Extravasation of leukocytes is mediated by the expression of different adhesion molecules on the surface of the leukocytes and the endothelium. PARPs have been shown to regulate the expression of adhesion molecules, such as ICAM-1 in various cell types including endothelial cells and cytokine-stimulated HaCaT keratinocytes (Zingarelli et al., 1998; Szabo et al., 2001) . Therefore, it is likely that in vivo inhibition of PARP activity may regulate the adhesion of the infiltrating cells to the vascular endothelium and thus influences the severity of inflammation in CHS. The other mechanism that may explain the inhibitory effect of PARP inhibition on the migration of inflammatory cells is the reduced expression of inflammatory cytokines (for example, tumor necrosis factor-a and IL-1b), with special regard to chemokines, the chemotactic cytokines. PARP-1 has been shown to act as a coactivator of NF-kB, a transcription factor involved in the expression of inflammatory mediators. This effect may explain the suppressing effect of the PARP inhibitor on the production of chemokines and cytokines in CHS.
Matrix metalloproteinases are now considered as inflammatory mediators as indicated by the anti-inflammatory effects of MMP inhibitors as demonstrated in various models of inflammation including CHS (Hu et al., 2007) . Active MMPs facilitate the movement of the infiltrating immune cells through the protein mesh of the extracellular matrix. MMP-9 expression is inducible in many cell types by proinflammatory cytokines such as tumor necrosis factora or IL-1b (Doller et al., 2007; Li et al., 2007) , and MMP-9 can be also be synthesized by a number of cell types in the inflamed skin, such as keratinocytes (Lamar et al. 2008) , granulocytes (Matsuzaki et al., 2006) , or dendritic cells (Zozulya et al., 2007) . As MMP expression is under the control of NF-kB (Bond et al., 1998) , inhibition of MMP-9 expression by PJ34 may be explained by the same mechanism as outlined above for inflammatory cytokines and chemokines. Moreover, the decrease of TIMP-2 may also lead to the activation of MMPs.
In summary, our data demonstrate that PARP activity mediates inflammation in CHS. PARP acts as a pleiotropic modulator of the inflammatory reaction by enhancing leukocyte migration, production of inflammatory cytokines and chemokines, and the activation of MMPs. Whether or not local PARP inhibition is a viable therapeutic approach in human CHS-like conditions requires further investigation, with special regard to a potential sensitizing effect of PARP inhibitors to carcinogenic stimuli.
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